Trastuzumab Emtansine Plus Pertuzumab Versus Taxane Plus Trastuzumab Plus Pertuzumab After Anthracycline for High-Risk Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer: The Phase III KAITLIN Study

We aimed to improve efficacy and reduce toxicity of high-risk human epidermal growth factor receptor 2 (HER2)–positive early breast cancer (EBC) treatment by replacing taxanes and trastuzumab with trastuzumab emtansine (T-DM1). METHODS: The phase III KAITLIN study (NCT01966471) included adults with...

Descripción completa

Detalles Bibliográficos
Autores principales: Krop, Ian E., Im, Seock-Ah, Barrios, Carlos, Bonnefoi, Hervé, Gralow, Julie, Toi, Masakazu, Ellis, Paul A., Gianni, Luca, Swain, Sandra M., Im, Young-Hyuck, De Laurentiis, Michelino, Nowecki, Zbigniew, Huang, Chiun-Sheng, Fehrenbacher, Louis, Ito, Yoshinori, Shah, Jigna, Boulet, Thomas, Liu, Haiying, Macharia, Harrison, Trask, Peter, Song, Chunyan, Winer, Eric P., Harbeck, Nadia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2022
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8824393/
https://www.ncbi.nlm.nih.gov/pubmed/34890214
http://dx.doi.org/10.1200/JCO.21.00896

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8824393/
https://www.ncbi.nlm.nih.gov/pubmed/34890214
http://dx.doi.org/10.1200/JCO.21.00896

Ejemplares similares